查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403502

2030 年重症肌无力治疗市场预测：按类型、药物类别、治疗方式、通路和地区进行的全球分析

Myasthenia Gravis Disease Treatment Market Forecasts to 2030 - Global Analysis By Type, Drug Class, Treatment Modality, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球重症肌无力治疗市场规模为 22 亿美元，预计在预测期内复合年增长率为 8.5%，到 2030 年将达到 39 亿美元。

重症肌无力（MG）治疗市场是指专注于治疗重症肌无力的药物和治疗领域，重症肌无力是一种以肌肉无力和疲劳为特征的慢性自体免疫神经肌肉疾病。该市场包括旨在控制重症肌无力患者症状、改善神经肌肉传导和提高整体生活品质的各种医疗干预措施。

根据国家罕见疾病组织 (NORD) 的数据，美国每 10 万人中约有 14 至 40 人患有重症肌无力。报告表明，近几十年来，重症肌无力的发生率一直在增加。这是由于患者识别更加容易以及全球自体自体免疫疾病的盛行率不断增加。

药品核准和管道开发

重症肌无力 (MG) 的治疗高度依赖管道开发和药物核准。新药的核准提供了更多的治疗选择，填补了市场空白，并改善了患者的治疗效果。正在进行的管道开发有望推进药物机制并提高疗效，表明我们致力于改进治疗方法。此外，这些进展可以为重症肌无力患者制定个体化和有针对性的治疗计划，减少副作用并改善管理。

缺乏疾病修正治疗

鑑于自体免疫疾病的复杂性和多因素性质，目前尚无可用于治疗重症肌无力（MG）的疾病修正治疗。与其他自体自体免疫疾病不同，导致重症肌无力的潜在机制尚未完全了解，这使得标靶治疗的开发变得困难。目前大多数治疗方法使用乙酰胆碱酯酶抑制剂和免疫抑制剂来控制症状，这些药物可以缓解症状，但无法解决根本原因。然而，儘管关于 MG 的精确机制和缓解疾病治疗方法的开发还有很多知识有待了解，但疾病的复杂性仍然是一个主要障碍。

联合治疗

联合治疗是一种很有前景的治疗方法，可以解决重症肌无力 (MG) 的不同方面。乙酰胆碱酯酶抑制剂和免疫抑制剂（例如皮质类固醇和免疫调节剂）协同作用，可控制 MG 特有的肌肉无力和自体免疫反应。此外，针对特定免疫途径的新型生物疗法可以与传统的医疗干预措施结合使用。透过解决复杂病理学的不同方面，联合治疗旨在最大限度地提高疗效，同时减少与大剂量单药相关的副作用。

患者反应的差异

重症肌无力患者患有复杂的自体免疫疾病，每个人对治疗的反应都不同。治疗结果取决于许多因素，包括共病、疾病严重程度和遗传变异。为了解决这个问题，正在研究精准医学方法，旨在根据患者的特定特征量身定制治疗方法。然而，製药公司和医疗专业人士仍然担心 MG 患者反应的固有变异性，这对市场上现有治疗性介入的标准化和优化具有影响。

COVID-19 的影响：

医疗保健服务和供应链的重大中断正在影响患者获得药物的机会，其中 COVID-19 已成为重症肌无力 (MG) 治疗市场的一个主要因素。远端医疗开闢了新的咨询选择，但血浆静脉注射和静脉注射免疫球蛋白 (IVIG) 等面对面治疗面临后勤挑战。此外，大流行的经济负担正在影响患者的负担能力和医疗预算，也影响了重症肌无力治疗的市场。儘管存在这些挑战，正在进行的研究和开发倡议仍在继续探索新的 MG治疗方法，以解决当前的障碍和潜在的未来市场动态。

胆碱酯酶抑制剂细分市场预计将在预测期内成为最大的细分市场

由于胆碱酯酶抑制剂在治疗自体自体免疫神经肌肉疾病症状的有效性，重症肌无力治疗市场正经历强劲成长。透过阻断乙酰胆碱的分解，吡斯的明等胆碱酯酶抑制剂对于改善神经肌肉传递至关重要，从而改善肌肉力量和功能。此外，随着重症肌无力治疗方法的改变以及更多医疗保健提供者将胆碱酯酶抑制剂纳入其综合治疗计划，预计市场将继续扩大。

静脉注射治疗领域预计在预测期内复合年增长率最高。

静脉治疗（IVT）因其能够快速缓解重症肌无力的急性症状而成为重症肌无力治疗市场中不断增长的部分。在治疗重症肌无力恶化时，静脉注射可以精确控制剂量并快速传递免疫抑制剂，例如静脉注射免疫球蛋白（IVIG）。在严重的情况下，这种治疗方法特别有用，因为它需要迅速采取行动来稳定患者的病情。此外，家庭 IVT 和输液技术便利性的提高为患者提供了更方便、更容易获得的治疗选择，从而支持了该细分市场的成长，从而推动了市场扩张。

占比最高的地区

由于重症肌无力 (MG) 盛行率上升、医疗设施改善以及公众对该疾病的认识不断提高，重症肌无力 (MG) 药物的销售量在亚太地区显着增加。该地区活性化的研发活动正在引入新的治疗方案。政府降低医疗保健成本和改善医疗保健可近性的计划对于促进市场扩张也至关重要。此外，重症肌无力的治疗模式不断变化，亚太地区对个人化医疗和生物技术进步的关注度不断提高，为这一发展做出了重大贡献。

复合年增长率最高的地区：

由于新治疗方法的推出、意识的提高和医学研究的改进，欧洲重症肌无力治疗市场不断增长。製药公司和医疗机构之间的合作正在促进扩大治疗选择。此外，该地区患者意识的提高和医疗基础设施的改善正在推动重症肌无力治疗市场的扩张。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球重症肌无力治疗市场：依类型

  • 全身性重症肌无力
  • 重症肌无力眼科
  • 新生儿短暂性重症肌无力
  • 其他类型

第六章全球重症肌无力治疗市场：依药物类别

  • 胆碱酯酶抑制剂
  • 单株抗体
  • 皮质类固醇
  • 免疫抑制剂
  • 静脉注射免疫球蛋白
  • 其他药物类别

第七章全球重症肌无力治疗市场：依治疗方式

  • 外科手术
  • 点滴疗法
  • 其他治疗方式

第八章全球重症肌无力治疗市场：依通路

  • 网路药房
  • 医院药房
  • 零售药房
  • 其他分销管道

第九章全球重症肌无力治疗市场：依地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 推出新药类别
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • AbbVie Inc.
  • Alexion Pharmaceutical Inc.
  • Amyasthenia gravisen inc.
  • Astellas pharma inc.
  • Astrazeneca
  • Avadel Pharmaceuticals plc
  • Bausch Health Companies Inc.
  • Baxter International, Inc.
  • Bayer ag
  • Biogen
  • Bristol-myers squibb
  • CSL Behring
  • Daiichi sankyo co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead sciences inc.
  • Glaxosmithkline plc.
  • Grifols SA
  • Merck & co. Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
  • Servier laboratories
  • Shire plc
  • Takeda Pharmaceutical Company Limited
  • Teva pharmaceutical industries ltd.
  • Valeant Pharmaceuticals International, Inc.
Product Code: SMRC24727

According to Stratistics MRC, the Global Myasthenia Gravis Treatment Market is accounted for $2.2 billion in 2023 and is expected to reach $3.9 billion by 2030 growing at a CAGR of 8.5% during the forecast period. The Myasthenia Gravis (MG) treatment market refers to the pharmaceutical and therapeutic landscape focused on addressing Myasthenia Gravis, a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. It encompasses a range of medical interventions aimed at managing symptoms, improving neuromuscular transmission, and enhancing the overall quality of life for individuals with MG.

According to the National Organization for Rare Disorders (NORD), in the U.S., around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders worldwide.

Market Dynamics:

Driver:

Drug approvals and pipeline developments

Treatment for myasthenia gravis (MG) is largely driven by pipeline advancements and drug approvals. New drug approvals provide more therapeutic options, filling gaps in the market and improving patient outcomes. A dedication to improving treatment modalities with potential advancements in drug mechanisms and increased efficacy is indicated by ongoing pipeline developments. Additionally, these developments could result in more individualized and focused treatment plans for MG patients, reducing side effects, and improving management.

Restraint:

Lack of disease-modifying therapies

Concerning the complex and multifactorial nature of autoimmune disorders, there are currently no disease-modifying therapies available for the treatment of myasthenia gravis (MG). Targeted therapy development is difficult because, unlike some other autoimmune diseases, the underlying mechanisms causing MG are not fully understood. The majority of current therapies use acetylcholinesterase inhibitors and immunosuppression to manage symptoms; they relieve symptoms but do not address the underlying cause. However, though there is still much to learn about the exact mechanisms underlying MG and the development of disease-modifying treatments, the disorder's complexity continues to be a major barrier.

Opportunity:

Combination therapies

Combination therapies provide a promising approach to treating myasthenia gravis (MG) by addressing various aspects of the disease. Acetylcholinesterase inhibitors and immunosuppressive medications, such as corticosteroids or immunomodulators, work in concert to manage MG's characteristic muscle weakness and autoimmune response. Additionally, novel biologic therapies that target particular immune pathways have the potential to be combined with conventional medical interventions. Combination therapies seek to maximize effectiveness while reducing side effects related to high dosages of individual medications by addressing different aspects of the intricate pathophysiology.

Threat:

Variability in patient response

Patients with Myasthenia Gravis have a complex autoimmune disorder, and their responses to therapies vary from person to person. Treatment outcomes vary depending on a number of factors, including comorbidities, disease severity, and genetic variations. To address this issue, precision medicine approaches are being investigated with the goal of customizing treatments based on unique patient characteristics. However, pharmaceutical companies and medical professionals continue to be concerned about the inherent variability in MG patient responses, which has an impact on the standardization and optimization of therapeutic interventions available on the market.

COVID-19 Impact:

Significant disruptions in healthcare services and supply chains have affected patient access to medications, making COVID-19 a major factor in the market for Myasthenia Gravis (MG) treatment. While telemedicine has opened up new consultation options, in-person treatments such as plasma exchange or intravenous immunoglobulin (IVIG) have encountered logistical difficulties. Furthermore, the pandemic's financial burden has affected patient affordability and healthcare budgets, which has affected the market for MG therapies. Not with standing these difficulties, ongoing research and development initiatives keep looking into novel MG treatments that address both present roadblocks and potential future market dynamics.

The cholinesterase inhibitors segment is expected to be the largest during the forecast period

The market for myasthenia gravis treatment has witnessed robust growth in the cholinesterase inhibitors segment because of the drug's effectiveness in treating the symptoms of the autoimmune neuromuscular disease. By stopping the breakdown of acetylcholine, cholinesterase inhibitors like pyridostigmine are essential in improving neuromuscular transmission and, consequently, muscle strength and function. Additionally, the market is expected to continue expanding as myasthenia gravis treatments change and more healthcare providers include cholinesterase inhibitors in all-encompassing treatment plans.

The intravenous therapy segment is expected to have the highest CAGR during the forecast period

Given its ability to quickly alleviate acute symptoms of the disease, intravenous therapy (IVT) has become a growing segment in the market for myasthenia gravis treatment. When it comes to treating Myasthenia gravis exacerbations, intravenous administration enables accurate dosage control and prompt delivery of immunosuppressive drugs like intravenous immunoglobulin (IVIG). In severe cases, this mode of therapy is especially helpful as it guarantees a prompt response in stabilizing patients. Furthermore, the convenience of in-home IVT and improvements in infusion technologies support the growth of this market segment by giving patients a more convenient and accessible treatment option, which in turn propels market expansion.

Region with largest share:

Myasthenia Gravis (MG) treatment sales have increased substantially in the Asia-Pacific region as a result of rising MG prevalence, improving healthcare facilities, and growing public awareness of the condition. New treatment options have been introduced as a result of an increase in research and development activities in the region. Government programs to improve healthcare affordability and accessibility have also been essential in promoting market expansion. Furthermore, the treatment landscape for myasthenia gravis is constantly changing, and the APAC region is a major contributor to this evolution with its growing emphasis on personalized medicine and biotechnology advancements.

Region with highest CAGR:

The European market for myasthenia gravis treatment is constantly growing as a result of new treatments being introduced, raising awareness, and improvements in medical research. The expansion of treatment options are facilitated by partnerships between pharmaceutical companies and healthcare organizations. Additionally, the region's growing patient awareness and improved healthcare infrastructure is propelling the market expansion for myasthenia gravis treatment.

Key players in the market:

Some of the key players in Myasthenia Gravis Treatment market include AbbVie Inc., Alexion Pharmaceutical Inc., Amyasthenia gravisen inc., Astellas pharma inc., Astrazeneca, Avadel Pharmaceuticals plc, Bausch Health Companies Inc., Baxter International, Inc., Bayer ag, Biogen, Bristol-myers squibb, CSL Behring, Daiichi sankyo co. Ltd., F. Hoffmann-La Roche Ltd., Gilead sciences inc., Glaxosmithkline plc., Grifols SA, Merck & co. Inc., Novartis AG, Pfizer, Inc., Sanofi, Servier laboratories, Shire plc, Takeda Pharmaceutical Company Limited, Teva pharmaceutical industries ltd. and Valeant Pharmaceuticals International, Inc.

Key Developments:

In December 2023, GSK announced that the European Commission (EC) has granted marketing authorization to its cancer drug, Jemperli (dostarlimab), for expanded use in primary advanced or recurrent endometrial cancer. The EC has now approved Jemperli in combination with carboplatin and paclitaxel as a frontline treatment for mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced/recurrent endometrial cancer in adult patients who are candidates for systemic therapy.

In December 2023, Moderna and Merck & Co said they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer. The therapy, V940, belongs to a class of treatments called m-RNA-based individualized neoantigen therapy (INT) and is tailored for each patient to generate T-cells, a key part of the body's immune response, based on the specific mutational signature of a tumour.

Drug Classes Covered:

  • Cholinesterase Inhibitors
  • Monoclonal Antibodies
  • Corticosteroids
  • Immunosuppressants
  • Intravenous Immunoglobulins
  • Other Drug Classes

Treatment Modalities Covered:

  • Surgery
  • Intravenous Therapy
  • Other Treatment Modalities

Types Covered:

  • Generalized Myasthenia Gravis
  • Ocular Myasthenia Gravis
  • Transient Neonatal Myasthenia Gravis
  • Other Types

Distribution Channels Covered:

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Myasthenia Gravis Disease Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Generalized Myasthenia Gravis
  • 5.3 Ocular Myasthenia Gravis
  • 5.4 Transient Neonatal Myasthenia Gravis
  • 5.5 Other Types

6 Global Myasthenia Gravis Disease Treatment Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Cholinesterase Inhibitors
  • 6.3 Monoclonal Antibodies
  • 6.4 Corticosteroids
  • 6.5 Immunosuppressants
  • 6.6 Intravenous Immunoglobulins
  • 6.7 Other Drug Classes

7 Global Myasthenia Gravis Disease Treatment Market, By Treatment Modality

  • 7.1 Introduction
  • 7.2 Surgery
  • 7.3 Intravenous Therapy
  • 7.4 Other Treatment Modalities

8 Global Myasthenia Gravis Disease Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Online Pharmacies
  • 8.3 Hospital Pharmacies
  • 8.4 Retail Pharmacies
  • 8.5 Other Distribution Channels

9 Global Myasthenia Gravis Disease Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Drug Class Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AbbVie Inc.
  • 11.2 Alexion Pharmaceutical Inc.
  • 11.3 Amyasthenia gravisen inc.
  • 11.4 Astellas pharma inc.
  • 11.5 Astrazeneca
  • 11.6 Avadel Pharmaceuticals plc
  • 11.7 Bausch Health Companies Inc.
  • 11.8 Baxter International, Inc.
  • 11.9 Bayer ag
  • 11.10 Biogen
  • 11.11 Bristol-myers squibb
  • 11.12 CSL Behring
  • 11.13 Daiichi sankyo co. Ltd.
  • 11.14 F. Hoffmann-La Roche Ltd.
  • 11.15 Gilead sciences inc.
  • 11.16 Glaxosmithkline plc.
  • 11.17 Grifols SA
  • 11.18 Merck & co. Inc.
  • 11.19 Novartis AG
  • 11.20 Pfizer, Inc.
  • 11.21 Sanofi
  • 11.22 Servier laboratories
  • 11.23 Shire plc
  • 11.24 Takeda Pharmaceutical Company Limited
  • 11.25 Teva pharmaceutical industries ltd.
  • 11.26 Valeant Pharmaceuticals International, Inc.

List of Tables

  • Table 1 Global Myasthenia Gravis Disease Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
  • Table 4 Global Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
  • Table 5 Global Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
  • Table 6 Global Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 8 Global Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 9 Global Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 10 Global Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 11 Global Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 12 Global Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
  • Table 13 Global Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 14 Global Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 15 Global Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 16 Global Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
  • Table 17 Global Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
  • Table 18 Global Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 19 Global Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 20 Global Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 21 Global Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 22 Global Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 23 North America Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 24 North America Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 25 North America Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
  • Table 26 North America Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
  • Table 27 North America Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
  • Table 28 North America Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 29 North America Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 30 North America Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 31 North America Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 32 North America Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 33 North America Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 34 North America Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
  • Table 35 North America Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 36 North America Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 37 North America Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 38 North America Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
  • Table 39 North America Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
  • Table 40 North America Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 41 North America Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 42 North America Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 43 North America Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 44 North America Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 45 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 46 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 47 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
  • Table 48 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
  • Table 49 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
  • Table 50 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 51 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 52 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 53 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 54 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 55 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 56 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
  • Table 57 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 58 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 59 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 60 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
  • Table 61 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
  • Table 62 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 63 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 64 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 65 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 66 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 67 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 68 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 69 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
  • Table 70 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
  • Table 71 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
  • Table 72 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 73 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 74 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 75 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 76 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 77 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 78 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
  • Table 79 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 80 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 81 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 82 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
  • Table 83 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
  • Table 84 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 85 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 86 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 87 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 88 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 89 South America Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 90 South America Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 91 South America Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
  • Table 92 South America Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
  • Table 93 South America Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
  • Table 94 South America Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 95 South America Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 96 South America Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 97 South America Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 98 South America Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 99 South America Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 100 South America Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
  • Table 101 South America Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 102 South America Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 103 South America Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 104 South America Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
  • Table 105 South America Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
  • Table 106 South America Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 107 South America Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 108 South America Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 109 South America Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 110 South America Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 111 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 112 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 113 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
  • Table 114 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
  • Table 115 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
  • Table 116 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 117 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 118 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 119 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 120 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 121 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 122 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
  • Table 123 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 124 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 125 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 126 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
  • Table 127 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
  • Table 128 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 129 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 130 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 131 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 132 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)